BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
Attruby (acoramidis) is an oral tablet for adults with cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM). The typical dosage is 2 tablets twice daily, swallowed whole ...
BridgeBio reports strong demand for Attruby post-FDA approval and enrollment completion in three Phase 3 trials, with significant financial backing. BridgeBio Pharma, Inc. announced significant ...
Zacks Investment Research on MSN
How a rival's clinical setback sent BBIO stock to a 52-week high
Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage clinical setback boosted investor confidence in the company's sole marketed ...
BridgeBio Pharma recently reported multiple developments, including new post-hoc analyses in Circulation: Heart Failure showing kidney-protective effects for approved ATTR-CM drug Attruby (acoramidis) ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...
BBIO’s Attruby (Acoramidis) delivers early, durable reductions in cumulative cardiovascular events. This candidate positions BBIO against Pfizer’s Tafamidis and Alnylam’s Amvuttra. Its US uptake keeps ...
BridgeBio Pharma BBIO is moving from a launch-driven story toward a broader commercial execution test. Attruby has quickly become the company’s financial backbone, while late-stage pipeline assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results